Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AACR’s “Most Likely To Succeed” Anticancer Technologies

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The AACR report celebrates “paradigm-shifting technologies and research areas that could dramatically accelerate advances against all types of cancer.” Some of the advanced technologies that the association thinks are “likely to be successful” include:

You may also be interested in...

Celgene Expands Agios Collaboration In Cancer Metabolism

Cancer metabolism specialist Agios extends research collaboration with Celgene, picking up an additional $20 million.

Eisai Deal Puts Epizyme In Position To Advance Lead Program

Deal with Eisai on epigenetic enzymes is collaborative, whereas in recent tie up with GSK, Epizyme gave up control of development and commercialization of select histone methyltransferases.

Taking Aim At Recurrence: Targeting Cancer Stem Cells To Stop Proliferation

An emerging field of oncology drug development offers the potential for eradicating all remaining cancer cells following treatment – and thus preventing recurrence – by targeting the so-called cancer stem cells that are thought to be involved in cancer proliferation, treatment resistance, and metastasis.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts